BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Inclinix, Inc. Announces New Patent for Expert System Platform


3/11/2008 9:57:48 AM

WILMINGTON, N.C., March 10 /PRNewswire/ -- Inclinix, Inc., an enrollment contract research organization (CRO) and provider of clinical trial recruitment solutions, announced today that it has received a patent for its Expert System Platform (ESP). ESP is a software system that guides interview questions during patient qualification for clinical trials of new drugs or medical devices.

Inclinix advertises to recruit patients into clinical trials. Respondents to Inclinix advertising answer questions on a Web site or when interacting via phone with Inclinix TeleMEDICINE(TM) Contact Center representatives. The questions posed to respondents determine if the respondents fit the inclusion and exclusion criteria from the trial sponsor, usually a pharmaceutical company.

ESP dynamically organizes questions for the interview, changing question order or removing questions depending on the answers. ESP is particularly helpful for simultaneous trials. The system can automatically switch the prospective trial candidate to questions for a sponsor's second, third or fourth trial if he or she does not qualify for the first one.

ESP inventor and Inclinix Chief Operating Officer Chris Sleat said: "The way that the system is built turns the previous interviewing automation processes and logic on its head. With ESP, the data defines the screening logic, so users do not have to think about the structure or dependencies of the interview. ESP is vastly superior to a static interview script."

ESP includes the ability to leverage data from prior volunteers who have elected to be included in a database for consideration in future trials. EPS works well in combination with internal reporting systems.

ESP also supports novel medical questionnaires, and the platform has been used in homeland security applications. The design supports interviewing patients in terrorist incidents to see if they are victims of weapons of mass destruction. The ESP system initiates questions about multiple possible weapons exposure and then narrows the inquiry based on answers.

The patent number for the Expert System Platform is 7330842.

About Inclinix

Founded in 1999, Inclinix, Inc., is the industry's Enrollment CRO. Inclinix's IQM(TM) Intelligent Enrollment process uses technology to amplify traditional services and is proven to accelerate trials for pharmaceutical, biotechnology and medical-device organizations. In addition to its clinical research-related offerings, Inclinix provides strategic medical marketing communications and adherence services to the healthcare industry. For more information on Inclinix, visit www.inclinix.com

CONTACT: Bill Gwinn of Inclinix, Inc., +1-910-332-2640,
bgwinn@inclinix.com

Web site: http://www.inclinix.com/


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->